A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT05658601 · clinicaltrials.gov ↗
COMPLETED
Status
104
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Bristol-Myers Squibb